Abstract: The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.

Abstract: A substrate includes a base, a pixel defining layer, a plurality of electrode pairs, and a plurality of light-emitting devices. The pixel defining layer is disposed on the base, and includes a plurality of through holes. At least one electrode pair includes a first electrode and a second electrode that are disposed at least on a hole wall of one of the through holes and at least partially opposite to each other, and the first electrode and the second electrode are insulated from each other. One of the plurality of light-emitting devices includes a liquid functional layer disposed in the through hole. The liquid functional layer is in direct contact with the first electrode and the second electrode. The liquid functional layer includes a liquid light-emitting layer configured to emit light.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are an image data reading method and apparatus, an electronic device, and a readable storage medium, relating to the technical field of LED image display. The image data reading method includes: storing image data in each row of image blocks into a number of v storage blocks, where each of the v storage blocks stores a number of h rows, each row of data including image data stored at a same position of each group in a same row of every image block; and sequentially outputting from each of the v storage blocks by: sequentially reading each row of the image data in a vertical order, and simultaneously outputting the image data stored at the same position.

Abstract: The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.

Abstract: Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.

Abstract: The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.

Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.

Abstract: The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.

Abstract: A wireless communication device (UE) may conduct wireless communications using one or more antennas according to multiple radio access technologies (RAT) associated with corresponding operating frequency bands. The UE may perform adaptive antenna tuning, for example, application-based antenna tuning for increasing the operating efficiency of the UE, which may improve user experience. The UE may periodically identify one or more applications running on the UE, the respective RATs that support the (running) applications, and which of the corresponding frequency bands are used by the (running) applications. The UE may determine the tuner device settings for tuning the one or more antenna(s) based on the (running) applications or the type and/or priority of the (running) applications, which RATs support the running applications, which of the corresponding frequency bands are used by the (running) applications, and operating conditions associated with the frequency bands used by the (running) applications.

Abstract: Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.

Abstract: An electronic device may include wireless communications circuitry that has first and second digital predistortion circuits. The first predistortion circuit receives a first signal at a first frequency while the second predistortion circuit receives a second signal at a second frequency. The first circuit may perform predistortion operations on the first signal using non-unity predistortion coefficients to generate a predistorted signal. The second circuit may apply unity predistortion coefficients to the second signal to generate an undistorted signal. An adder may combine the predistorted and undistorted signals to generate a combined signal that is amplified by amplifier circuitry. An antenna may transmit the amplified signal.

Abstract: An electronic device may include wireless communications circuitry that has first and second digital predistortion circuits. The first predistortion circuit receives a first signal at a first frequency while the second predistortion circuit receives a second signal at a second frequency. The first circuit may perform predistortion operations on the first signal using non-unity predistortion coefficients to generate a predistorted signal. The second circuit may apply unity predistortion coefficients to the second signal to generate an undistorted signal. An adder may combine the predistorted and undistorted signals to generate a combined signal that is amplified by amplifier circuitry. An antenna may transmit the amplified signal.

Abstract: Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.